Medication access healthcare IT solution provider ScriptDrop has just raised $15m in Series A funding. In conjunction with the round announcement, CEO Amanda Epp answered our questions about the herself, the company, the round and future plans.
FinSMEs: Hi Amanda, can you tell us a bit more about you. What’s your background?
Amanda: Before joining the ScriptDrop community, I was the first hired employee at CoverMyMeds, a healthcare IT company that sold for more than $1 billion to McKesson Corporation in 2017. At CoverMyMeds, I played an integral role in the company’s exponential growth and eventually became Director of New Product Implementation. I joined ScriptDrop as one of their first employees, and served as president before assuming the CEO position.
FinSMEs: Let’s speak about ScriptDrop. Which is the market problem do you want to solve? Which is the real opportunity?
Amanda: ScriptDrop’s core mission is to expand access to medication across the globe. We believe that medication should be as accessible as any other e-commerce platforms that enable one-click orders.
FinSMEs: How does it work? Which are the main features?
Amanda: We have both a pharmacy-focused offering as well as a consumer-facing portal. Each channel enables medication access. We partner with both small pharmacies and major chains to provide delivery of medication as quickly as day-of. Our network allows us to deliver medication to any consumer across the country, no matter their destination or their preferred pharmacy.
FinSMEs: What are the features differentiating the product from competitors?
Amanda: ScriptDrop allows consumers to fill prescriptions from their preferred pharmacy, delivered to their doorstep. We’re a prescription delivery solution, not a dispensing pharmacy. We leave filling medication to pharmacists — instead, we partner with pharmacies small and large to deliver directly to consumers. Additionally, we partner with a vast network of courier companies to ensure timely delivery of medications via our simplified texting solution.
FinSMEs: You just raised a new funding round. Please, tell us something more about it…
Amanda: We’ll be using this round to focus on engineering and operations and continuing to scale our business to help more patients.
FinSMEs: Can you share some numbers and achievements of your business?
Amanda: The company experienced a 363% delivery volume increase from February to April 2020, and between last year at this time and this year there was a 220% increase in revenue (2019-2020). We’ve also grown to 100 employees in just over three years.
FinSMEs: What’s your medium-term plans?
Amanda: We will continue to focus on expanding access to medication across the globe.